teva: search

Teva Announces Agreement on Generic Pulmicort Respules Patent Challenge

Teva Pharmaceutical Industries Ltd. has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva’s U.S. generic version of AstraZeneca’s Pulmicort (Budesonide) Respules® including all claims for patent infringement and damages. Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The agreement releases Teva for all past U.S. sales of its generic budesonide respules and provides that any product already shipped by Teva will remain in the market to be further distributed and dispensed. Teva will not resume shipping additional units of its budesonide respules until December 15, 2009 (or earlier based on certain contingencies) pursuant to an exclusive license for which Teva will pay AstraZeneca an undisclosed royalty.

BRIEF: Gilead sues Teva for HIV patent infringement: Teva has applied to the FDA to make and market generic Truvada.

Dec. 14--Gilead Sciences Inc. (Nasdaq: GILD) has sued Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and subsidiary Teva Pharmaceuticals USA Inc. for patent infringement. The lawsuit, filed on Friday with a US District Court in New York, states that Teva has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for approval to produce and sell a generic version of Truvada, a treatment of HIV-1 in adults, before the expiration two related patents.

Gilead sues Teva for HIV patent infringement

Gilead Sciences Inc. (Nasdaq: GILD) has sued Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and subsidiary Teva Pharmaceuticals USA Inc. for patent infringement. The lawsuit, filed on Friday with a US District Court in New York, states that Teva has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for approval to produce and sell a generic version of Truvada, a treatment of HIV-1 in adults, before the expiration two related patents.

Teva?s patents for cardiac drug are invalid: Glenmark

Mumbai: Challenging the near-monopoly of global generic giant Teva Pharmaceutical Industries Ltd in the about $2 billion (nearly Rs10,000 crore) US market for the cardiac drug carvedilol, India’s Glenmark Pharmaceuticals Ltd has filed its counterclaims in the US district court of New Jersey, claiming Teva’s two patents for making the drug is invalid and unenforceable.

Gilead Sciences files patent lawsuit against Teva Pharmaceuticals over HIV drug

Gilead Sciences Inc. has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA Inc. and Teva Pharmaceutical Industries Ltd. for infringement of two patents associated with the HIV drug Truvada.

Gilead files patent infringement lawsuit against Teva

said late Friday it has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA and Teva Pharmaceutical Industries

Gilead files patent infringement lawsuit against Teva

Singapore, Dec 15, 2008: Gilead Sciences has filed a lawsuit in US District Court in New York against Teva Pharmaceuticals USA and Teva Pharmaceutical Industries for infringement of US Patent Numbers 6,642,245 and 6,703,396.

Gilead files patent infringement lawsuit against Teva Pharma

Gilead Sciences, Inc. announced that it has filed a lawsuit in US District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of US Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada (emtricitabine and tenofovir disoproxil fumarate), and are licensed exclusively to Gilead Sciences by Emory University. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Gilead Sciences Files Patent Infringement Lawsuit Against Teva

Gilead Sciences, Inc. has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada® (emtricitabine and tenofovir disoproxil fumarate), and are licensed exclusively to Gilead Sciences by Emory University. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Gilead Sciences Files Patent Infringement Lawsuit Against Teva

Gilead Sciences, Inc. GILD today announced that it has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada

Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec 12, 2008 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada

Gilead Sciences (GILD) Files Patent Infringement Suit Against Teva Pharmaceuticals (TEVA)

Top 10 News Items 12/8-12/12: Madoff Shocks the Investment World; House Turns Down Auto Bailout Bill; Large Scale Layoffs Continue

Teva, Pfizer Both Score Wins In Detrol Patent Fight

Law360, New York (December 10, 2008) -- Pfizer Inc. and Teva Pharmaceuticals Industries Ltd. have each notched victories in a patent suit over Pfizer's prescription bladder control drug Detrol.

Teva to Present at the 27th Annual J.P. Morgan Healthcare Conference

Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer and William Marth, President and CEO, Teva North America, will present on Monday, January 12, 2009.

Teva to Present at the 27th Annual J.P. Morgan Healthcare Conference

will host a live audio webcast at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer and William Marth, President and CEO, Teva North America, will present on Monday, January 12, 2009.

Tel Aviv shares lower, as Teva sued over patent

TEL AVIV (MarketWatch) -- Israeli stocks fell for a second day, led lower by Bank Leumi, Makhteshim-Agan and Teva Pharmaceutical, as well as some key tech names.

Israel Stocks: Tel Aviv shares lower, as Teva sued over patent

TEL AVIV (MarketWatch) -- Israeli stocks fell for a second day, led lower by Bank Leumi, Makhteshim-Agan and Teva Pharmaceutical, as well as some key tech names.

Search took 0.02 seconds.